| | |
| | |
| Clinical data | |
|---|---|
| Trade names | Abasol |
| Routes of administration | Topical (cream) |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.125.129 |
| Chemical and physical data | |
| Formula | C21H22N4OS |
| Molar mass | 378.49 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Abafungin (INN) is a broad-spectrum arylguanidines-class antifungal agent with a novel mechanism of action for the treatment of dermatomycoses. [1]
Abasol is a topical cream formulation of abafungin by York Pharma. [2]
Abafungin was first synthesized at Bayer AG, Leverkusen, Germany. A study of H2-antagonists related to famotidine, resulted in the discovery of its antifungal properties. [3]
Its development seems to have been discontinued in 2009. [4]
Unlike imidazole- and triazole-class antifungals, abafungin directly impairs the fungal cell membrane. [3]
In addition, abafungin inhibits the enzyme sterol 24-C-methyltransferase, modifying the composition of the fungal membrane. [5]
Abafungin has antibiotic activity against gram-positive bacteria as well as sporicidal activity. [6]